
Novel dual ингибитор of the canonical and noncanonical NF-κB pathways, increasing the magnitude and duration of initial EGFR ингибитор response in multiple NSCLC models, decreasing PDHK1 expression, and suppressing phosphorylation of the PDHK1 protein sub
Novel dual inhibitor of the canonical and noncanonical NF-κB pathways, increasing the magnitude and duration of initial EGFR inhibitor response in multiple NSCLC models, decreasing PDHK1 expression, and suppressing phosphorylation of the PDHK1 protein sub
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.